DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 12:14:43 2024-06-11 pm EDT | ||
| 278 EUR | +0.19% |
|
| Current month | +1.11% | ||
| 1 month | +0.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 278 | +0.19% |
| 24-06-10 | 277.5 | +0.47% |
| 24-06-07 | 276.2 | +0.76% |
| 24-06-06 | 274.1 | -0.13% |
| 24-06-05 | 274.5 | +0.21% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 12:14 pm EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7D8N |
| ISIN | DE000ME7D8N7 |
| Date issued | 2024-01-23 |
| Maturity | 2024-09-20 (101 Days) |
| Parity | 1 : 1 |
| Emission price | 268.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 278 € |
|---|---|
| Lowest since issue | 263 € |
| Spread | 0.32 € |
| Spread % | 0.12% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483.3
USD
Average target price
463.4
USD
Spread / Average Target
-4.11%
- Stock Market
- Certificates
- Certificat
